Maze Therapeutics rises as kidney disease drug shows positive results in trial

Shares of biotech firm Maze Therapeutics MAZE.O rise 3.1% to $50.50 premarket

Co says its experimental drug MZE829 reduced protein in urine, a key sign of kidney damage, in a mid‑stage study

Drug targets APOL1‑mediated kidney disease, an inherited kidney condition that can lead to kidney failure

Study showed an average 35.6% drop in urine protein after 12 weeks; about half of patients saw drops of over 30%, co says

Adds larger reductions were seen in patients with a severe kidney scarring condition and those without diabetes

Co says it plans a larger, late‑stage study of MZE829 following the results

As of last close, stock was up ~18% YTD